Zobrazeno 111 - 120
of 162 694
pro vyhledávání: ''
Autor:
Elisa Pasqual, Sara Schonfeld, Lindsay M. Morton, Daphnée Villoing, Choonsik Lee, Amy Berrington de Gonzalez, Cari M. Kitahara
Publikováno v:
J Clin Oncol
PURPOSE Since the 1980s, both the incidence of differentiated thyroid cancer (DTC) and use of radioactive iodine (RAI) treatment increased markedly. RAI has been associated with an increased risk of leukemia, but risks of second solid malignancies re
Publikováno v:
Clin Lymphoma Myeloma Leuk
Multiple myeloma is primarily a disease of the elderly, and optimal treatments must weigh the risks of toxicity with the benefits of therapy. Frailty scales have been developed to aid treatment-decision making for older adults with MM. This review pr
Autor:
Thomas Prebet, Aaron D. Goldberg, Joseph G. Jurcic, Samer Khaled, Monique Dail, Yuning Feng, Cherie Green, Chunze Li, Connie Ma, Bruno C. Medeiros, Mark Yan, Michael R. Grunwald
Publikováno v:
Leukemia & Lymphoma. 63:2180-2188
This phase 1 b study evaluated the safety, efficacy, and pharmacokinetics of atezolizumab in combination with guadecitabine in patients with relapsed/refractory (R/R) or first-line acute myeloid leukemia (AML). Patients received atezolizumab 840 mg (
Autor:
Reshma, Jagsi, Kent A, Griffith, Frank, Vicini, Thomas, Boike, Michael, Dominello, Gregory, Gustafson, James A, Hayman, Jean M, Moran, Jeffrey D, Radawski, Eleanor, Walker, Lori, Pierce, Vrinda, Narayana
Publikováno v:
JAMA Oncol
IMPORTANCE: Understanding whether physicians accurately detect symptoms in patients with breast cancer is important because recognition of symptoms facilitates supportive care, and clinical trials often rely on physician assessments using Common Toxi
Autor:
Elizabeth Bancroft, Chee Goh, Elizabeth Page, Zsofia Kote-Jarai, Elena Castro, Christos Mikropoulos, Edward J. Saunders, Nandita M. deSouza, David E. Neal, Stephen Hazell, Antonis C. Antoniou, Natalie Taylor, Pardeep Kumar, Nigel Borley, Rosalind A. Eeles, Freddie C. Hamdy, Sibel Saya, Naomi Livni, Diana Keating, Tokhir Dadaev
Publikováno v:
The Oncologist
A better assessment of prostate cancer (PrCa) risk is needed to improve screening. The PROFILE pilot study explored the feasibility of single nucleotide polymorphism profiling in men with a family history (FH) of PrCa to investigate the probability o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::530db08f3b0071b7ef326b41d3c41f1a
https://ora.ox.ac.uk/objects/uuid:5985ee3f-ba82-44cd-9894-a0e866e55da9
https://ora.ox.ac.uk/objects/uuid:5985ee3f-ba82-44cd-9894-a0e866e55da9
Autor:
David M. O'Malley, Maryna Neffa, Bradley J. Monk, Tamar Melkadze, Marilyn Huang, Anna Kryzhanivska, Iurie Bulat, Tarek M. Meniawy, Andrea Bagameri, Edward W. Wang, Bernard Doger de Speville Uribe, Roberto Hegg, Waldo Ortuzar Feliu, Marek Ancukiewicz, Iwona Lugowska
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(7)
PURPOSE Balstilimab (antiprogrammed death-1) and zalifrelimab (anticytotoxic T-lymphocyte–associated antigen-4) are two new checkpoint inhibitors emerging as promising investigational agents for the treatment of advanced cervical cancer. This phase
Autor:
Ian E. Krop, Seock-Ah Im, Carlos Barrios, Hervé Bonnefoi, Julie Gralow, Masakazu Toi, Paul A. Ellis, Luca Gianni, Sandra M. Swain, Young-Hyuck Im, Michelino De Laurentiis, Zbigniew Nowecki, Chiun-Sheng Huang, Louis Fehrenbacher, Yoshinori Ito, Jigna Shah, Thomas Boulet, Haiying Liu, Harrison Macharia, Peter Trask, Chunyan Song, Eric P. Winer, Nadia Harbeck
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(5)
PURPOSE We aimed to improve efficacy and reduce toxicity of high-risk human epidermal growth factor receptor 2 (HER2)–positive early breast cancer (EBC) treatment by replacing taxanes and trastuzumab with trastuzumab emtansine (T-DM1). METHODS The
Autor:
Thorsten Lehr, Hannah Britz, Clinton F. Stewart, Daniel Moj, Walter E. Haefeli, Gerlinde Egerer, Jürgen Burhenne
This study aimed at recommending pediatric dosages of the histone deacetylase (HDAC) inhibitor vorinostat and potentially more effective adult dosing regimens than the approved standard dosing regimen of 400 mg/day, using a comprehensive physiologica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b42701510c1983fe755fd57a7800a87
Autor:
Daniel Moj, Nicola Ammer, Babette Aicher, Jan-Georg Wojtyniak, Thorsten Lehr, Michael Teifel, Herbert Sindermann, Hannah Britz, Nina Hanke
Zoptarelin doxorubicin is a fusion molecule of the chemotherapeutic doxorubicin and a luteinizing hormone-releasing hormone receptor (LHRHR) agonist, designed for drug targeting to LHRHR positive tumors. The aim of this study was to establish a physi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28c5e9a18956370d7aca5ee1061fd910
Autor:
Manabu, Emi, Yoichi, Hmai, Toru, Yoshikawa, Ryosuke, Hirohata, Manato, Osawa, Morihito, Okada, Yuji, Murakami, Ikuno, Nishibuchi
Publikováno v:
Anticancer Research. 42:2791-2795
Surgical resection and chemoradiotherapy (CRT) can be performed as additional treatments for superficial esophageal cancer after endoscopic resection, but the selection criteria vary depending on the institution. We retrospectively evaluated the outc